🇺🇸 FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11654145

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648307

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648302

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642366

Methods for preventing a serious health consequence and/or tissue damage after exposure to

GLYCOMIRA THERAPEUTICS, INC. · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642401

Activation of resident memory T cells for cancer immunotherapy

Regents of the University of Minnesota · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642374

Intracellular genomic transplant and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642375

Intracellular genomic transplant and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11640848

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burde

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11638753

Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dend

PDS Biotechnology Corporation · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11631483

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11612652

Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dend

PDS Biotechnology Corporation · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608367

Peptides for angiogenic therapy

The Regents of the University of California · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11607557

Devices and systems for treating pain based on light therapy

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596694

Compositions and methods for predicting response to NaPi2b-targeted therapy

Mersana Therapeutics, Inc. · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596671

Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with in

Takeda Pharmaceutical Company Limited · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591402

Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy

The Regents of the University of California · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11591579

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

The Board of Regents of the University of Texas System · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11583556

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578371

Biomarkers for predicting tumor response to and toxicity of immunotherapy

MIRA DX, INC. · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11576883

L-DOPA microbiome therapy

The Board of Regents of the University of Texas System · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted